Oligonucleotide Synthesis Market

Short single strands of synthetic DNA or RNA called oligonucleotides, or oligos, are the basis for many molecular biology and synthetic biology applications. An oligo might be the starting point for anything from genetic testing to forensic analysis and next-generation sequencing. Increased usage of oligonucleotides has motivated the need for technological developments in synthetic chemistry. Now various biotechnology and pharma companies are developing new and advanced methods. Recently, Integrated DNA Technologies has developed oligonucleotides up to 200 base lengths which could be used for manufacturing mini-genes with the help of mass spectrometry.

Current Market and Key Drivers

Global Market size for Oligonucleotide synthesis was $7.7 billion in 2022 and is expected to reach $26.61 by 2030 at a CAGR of 17.6% in the forecast period of 2023-2030. The major that is driving the growth of this market is increasing focus on personalized genome sequencing which helps to determine the best approach for patient care, whether preventive, diagnostic, or therapeutic. Furthermore, in recent years, many countries have made significant investments in synthetic biology and genomics projects. These government investments were the major reason for the development of new technologies.

Synthetic oligos as therapeutic drugs played important role in the treatment of diseases in the last decade. Viral infections, respiratory diseases, cancer, and rare diseases like Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura could be treated very effectively by using Therapeutic oligos. These are some reasons which motivate governments to invest in this market.

Major players in this market are Alnylam Pharmaceuticals Inc., Biogen Limited, Cinven, Danaher Corporation, Eurofins Scientific, Ionis Pharmaceuticals, Inc., Kaneka Corporation, Merck Kgaa, Sarepta Therapeutics, Inc., Thermo Fisher Scientific Inc.

In 2020, Danaher Corporation (US) opened IDT China to serve its regional customer base, and acquire new customers. Also, Danaher acquired the Biopharma company from the Life Sciences division of General Electric Company. This acquisition has strengthened Danaher’s position in the oligo synthesizer and reagents market.

Major and Growing Geographies

North America, comprising the US and Canada, are largest regional segment for the oligonucleotide synthesis market. In 2021, North America has the largest market share of oligonucleotide synthesis. The oligonucleotide synthesis market is expected to flourish in the coming years due to the potential of therapeutic oligos in cancer diseases. Almost 1.9 million new instances of cancer are anticipated to be diagnosed in the United States in 2022, according to Cancer Facts and Statistics 2022. Also, according to figures from Breastcancer.org for 2022, there are predicted to be 51,400 new instances of non-invasive (in situ) breast cancer and 287,850 new cases of invasive breast cancer in the United States in that year. The rising incidence of cancer among the population increases the need for cutting-edge treatments, driving up the price of oligonucleotide therapies and accelerating market expansion.

High Growth Market segments

The Oligonucleotide Synthesis Market is expected to be dominated by the category of oligonucleotide synthesis products. A higher percentage of synthesis products is the result of the widespread usage of synthesizers and consumables in PCR investigations, such as PCR primers. Due to its simplicity, high sensitivity, and cost-effectiveness, PCR technologies are widely used in research and diagnostic domains, which is boosting the expansion of this market.

According to the application, the research sector is anticipated to hold the greatest market share for oligonucleotide synthesis in 2019. However, due to the growing uses of molecular diagnostics (MDx) and genetic testing, the use of oligonucleotides for diagnostic applications is predicted to expand at the quickest CAGR during the projected period.

Hospitals, pharmaceutical and biotechnology firms, diagnostic laboratories, CROs and CMOs, and academic research institutions are the different end-user categories. In 2020, the hospital segment led the market for oligonucleotide synthesis globally, and it is projected that this dominance will persist over the coming years. This is explained by a large number of inpatient and outpatient visits to hospitals as well as the increased demand for oligonucleotide medications to meet the rising demand from patients with infectious diseases, uncommon diseases, and neurological disorders.

Conclusion

An oligo might be the starting point for anything from genetic testing to forensic analysis and next-generation sequencing. Viral infections, respiratory diseases, cancer, and rare diseases like Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura could be treated very effectively by using Therapeutic oligos. Focus on personalized genome sequencing which helps to determine the best approach for patient care, whether preventive, diagnostic, or therapeutic is driving this market’s growth. The Global Market size for Oligonucleotide synthesis was $7.7 billion in 2022 and is expected to be at a CAGR of 17.6% in the forecast period of 2023-2030. North America, comprising the US and Canada, are largest regional segment for the oligonucleotide synthesis market. Oligonucleotide synthesis products, the research sector, and Hospitals are the major and highest-growth segments of the oligonucleotide synthesis market.